Your browser doesn't support javascript.
loading
Immunological effects and activity of multiple doses of zolbetuximab in combination with zoledronic acid and interleukin-2 in a phase 1 study in patients with advanced gastric and gastroesophageal junction cancer.
Lordick, Florian; Thuss-Patience, Peter; Bitzer, Michael; Maurus, Daniel; Sahin, Ugur; Türeci, Özlem.
Affiliation
  • Lordick F; Department of Oncology, Gastroenterology, Hepatology, and Pulmonology, Comprehensive Cancer Center Central Germany (CCCG), University of Leipzig Medical Center, Liebigstraße 22, 04103, Leipzig, Germany. florian.lordick@medizin.uni-leipzig.de.
  • Thuss-Patience P; Department of Hematology, Oncology and Tumor Immunology, Charité-University Medicine Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany.
  • Bitzer M; Department of Internal Medicine I, University Hospital, Eberhard Karls University Tuebingen, Otfried-Müller-Straße 10, 72076, Tübingen, Germany.
  • Maurus D; Ganymed Pharmaceuticals GmbH (Formerly Ganymed Pharmaceuticals AG), Mainz, Germany.
  • Sahin U; Biopharmaceutical New Technologies (BioNTech) Corporation, An der Goldgrube 12, 55131, Mainz, Germany.
  • Türeci Ö; Ci3-Cluster of Individualized Immune Intervention, Mainz, Germany.
J Cancer Res Clin Oncol ; 149(9): 5937-5950, 2023 Aug.
Article in En | MEDLINE | ID: mdl-36607429
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Stomach Neoplasms / Adenocarcinoma Type of study: Clinical_trials Limits: Humans Language: En Journal: J Cancer Res Clin Oncol Year: 2023 Type: Article Affiliation country: Germany
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Stomach Neoplasms / Adenocarcinoma Type of study: Clinical_trials Limits: Humans Language: En Journal: J Cancer Res Clin Oncol Year: 2023 Type: Article Affiliation country: Germany